These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 38069638)

  • 21. An optimized protocol for the in vitro generation and functional analysis of human PD1/PD-L1 signal.
    Khedri M; Abnous K; Rafatpanah H; Ramezani M
    J Recept Signal Transduct Res; 2018 Feb; 38(1):31-36. PubMed ID: 29252078
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells.
    Suriyo T; Fuangthong M; Artpradit C; Ungtrakul T; Sricharunrat T; Taha F; Satayavivad J
    Eur J Pharmacol; 2021 Apr; 897():173960. PubMed ID: 33617828
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Glial cells suppress postencephalitic CD8+ T lymphocytes through PD-L1.
    Schachtele SJ; Hu S; Sheng WS; Mutnal MB; Lokensgard JR
    Glia; 2014 Oct; 62(10):1582-94. PubMed ID: 24890099
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Programmed cell death ligand 1 alleviates psoriatic inflammation by suppressing IL-17A production from programmed cell death 1-high T cells.
    Kim JH; Choi YJ; Lee BH; Song MY; Ban CY; Kim J; Park J; Kim SE; Kim TG; Park SH; Kim HP; Sung YC; Kim SC; Shin EC
    J Allergy Clin Immunol; 2016 May; 137(5):1466-1476.e3. PubMed ID: 26824999
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunosuppression of Human Adipose-Derived Stem Cells on T Cell Subsets via the Reduction of NF-kappaB Activation Mediated by PD-L1/PD-1 and Gal-9/TIM-3 Pathways.
    Zhou K; Guo S; Tong S; Sun Q; Li F; Zhang X; Qiao Y; Liang G
    Stem Cells Dev; 2018 Sep; 27(17):1191-1202. PubMed ID: 29978730
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Uncovering the colorectal cancer immunotherapeutic potential: Evening primrose (Oenothera biennis) root extract and its active compound oenothein B targeting the PD-1/PD-L1 blockade.
    Lee EJ; Kim YS; Kim JH; Woo KW; Park YH; Ha JH; Li W; Kim TI; An BK; Cho HW; Han JH; Choi JG; Chung HS
    Phytomedicine; 2024 Mar; 125():155370. PubMed ID: 38266440
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo.
    Ito T; Ueno T; Clarkson MR; Yuan X; Jurewicz MM; Yagita H; Azuma M; Sharpe AH; Auchincloss H; Sayegh MH; Najafian N
    J Immunol; 2005 Jun; 174(11):6648-56. PubMed ID: 15905503
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Programmed Cell Death-1: Programmed Cell Death-Ligand 1 Interaction Protects Human Cardiomyocytes Against T-Cell Mediated Inflammation and Apoptosis Response In Vitro.
    Tay WT; Fang YH; Beh ST; Liu YW; Hsu LW; Yen CJ; Liu PY
    Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32244307
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Blockade of B7-H1 on macrophages suppresses CD4+ T cell proliferation by augmenting IFN-gamma-induced nitric oxide production.
    Yamazaki T; Akiba H; Koyanagi A; Azuma M; Yagita H; Okumura K
    J Immunol; 2005 Aug; 175(3):1586-92. PubMed ID: 16034097
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Thyroid cells from normal and autoimmune thyroid glands suppress T lymphocytes proliferation upon contact revealing a new regulatory inhibitory type of interaction independent of PD1/PDL1.
    Álvarez-Sierra D; Sánchez-Gaona N; Cruz Cobo M; Escriche A; Abad M; Gómez-Brey A; Bello I; Caubet E; González Ó; Zafón C; Iglesias C; Moreno P; Petit A; Fernández-Sanmartín MA; Martínez-Gallo M; Pujol-Borrell R
    J Autoimmun; 2023 Apr; 136():103013. PubMed ID: 36857863
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human adipose-derived mesenchymal stem cells prevent type 1 diabetes induced by immune checkpoint blockade.
    Kawada-Horitani E; Kita S; Okita T; Nakamura Y; Nishida H; Honma Y; Fukuda S; Tsugawa-Shimizu Y; Kozawa J; Sakaue T; Kawachi Y; Fujishima Y; Nishizawa H; Azuma M; Maeda N; Shimomura I
    Diabetologia; 2022 Jul; 65(7):1185-1197. PubMed ID: 35511238
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sanguisorbae Radix Suppresses Colorectal Tumor Growth Through PD-1/PD-L1 Blockade and Synergistic Effect With Pembrolizumab in a Humanized PD-L1-Expressing Colorectal Cancer Mouse Model.
    Lee EJ; Kim JH; Kim TI; Kim YJ; Pak ME; Jeon CH; Park YJ; Li W; Kim YS; Choi JG; Chung HS
    Front Immunol; 2021; 12():737076. PubMed ID: 34659228
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The PD-L1/4-1BB Bispecific Antibody-Anticalin Fusion Protein PRS-344/S095012 Elicits Strong T-Cell Stimulation in a Tumor-Localized Manner.
    Peper-Gabriel JK; Pavlidou M; Pattarini L; Morales-Kastresana A; Jaquin TJ; Gallou C; Hansbauer EM; Richter M; Lelievre H; Scholer-Dahirel A; Bossenmaier B; Sancerne C; Riviere M; Grandclaudon M; Zettl M; Bel Aiba RS; Rothe C; Blanc V; Olwill SA
    Clin Cancer Res; 2022 Aug; 28(15):3387-3399. PubMed ID: 35121624
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic value of programmed death-1, programmed death-ligand 1, programmed death-ligand 2 expression, and CD8(+) T cell density in primary tumors and metastatic lymph nodes from patients with stage T1-4N+M0 gastric adenocarcinoma.
    Gao Y; Li S; Xu D; Chen S; Cai Y; Jiang W; Zhang X; Sun J; Wang K; Chang B; Wang F; Hong M
    Chin J Cancer; 2017 Jul; 36(1):61. PubMed ID: 28754154
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development and functional analysis of an anticancer T-cell medicine with immune checkpoint inhibitory ability.
    Fujiwara K; Shigematsu K; Tachibana M; Okada N
    IUBMB Life; 2020 Aug; 72(8):1649-1658. PubMed ID: 32255257
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PD-L1 enhances CNS inflammation and infarct volume following experimental stroke in mice in opposition to PD-1.
    Bodhankar S; Chen Y; Vandenbark AA; Murphy SJ; Offner H
    J Neuroinflammation; 2013 Sep; 10():111. PubMed ID: 24015822
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel strategies for inhibiting PD-1 pathway-mediated immune suppression while simultaneously delivering activating signals to tumor-reactive T cells.
    Ostrand-Rosenberg S; Horn LA; Alvarez JA
    Cancer Immunol Immunother; 2015 Oct; 64(10):1287-93. PubMed ID: 25792524
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Blockade of LAG-3 in PD-L1-Deficient Mice Enhances Clearance of Blood Stage Malaria Independent of Humoral Responses.
    Furtado R; Chorro L; Zimmerman N; Guillen E; Spaulding E; Chin SS; Daily JP; Lauvau G
    Front Immunol; 2020; 11():576743. PubMed ID: 33519801
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An Fc-inert PD-L1×4-1BB bispecific antibody mediates potent anti-tumor immunity in mice by combining checkpoint inhibition and conditional 4-1BB co-stimulation.
    Muik A; Altintas I; Gieseke F; Schoedel KB; Burm SM; Toker A; Salcedo TW; Verzijl D; Eisel D; Grunwitz C; Kranz LM; Vormehr M; Satijn DPE; Diken M; Kreiter S; Sasser K; Ahmadi T; Türeci Ö; Breij ECW; Jure-Kunkel M; Sahin U
    Oncoimmunology; 2022; 11(1):2030135. PubMed ID: 35186440
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Striking dichotomy of PD-L1 and PD-L2 pathways in regulating alloreactive CD4(+) and CD8(+) T cells in vivo.
    Habicht A; Kewalaramani R; Vu MD; Demirci G; Blazar BR; Sayegh MH; Li XC
    Am J Transplant; 2007 Dec; 7(12):2683-92. PubMed ID: 17924994
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.